Meibomian gland dysfunction (MGD) is one of the most common ophthalmologic conditions worldwide. The clinical spectrum of the disease varies. Patients with mild MGD only experience chronic discomfort. Patients with severe dysfunction experience a decrease in vision and then become blind. The pathology of MGD involves meibomian gland destruction and an increase in lipid viscosity that blocks the pore, causing a reduction in glandular lipid secretion and discharge. This leads to a lack of the lipid layer in tear film, therefore causing damage to the ocular surface epithelial cells and inflammation. The keratoconjunctivitis associated with MGD occurs at the inferior corneal area that is in contact with the palpebral margin. Corneal tissue infiltrates the blood vessels. Some patients also suffer from acne and sebaceous gland disorder. Treatment includes cleaning the palpebral margin, supple artificial tear liquid, and treatment for infection and inflammation that prevents ocular tissue damage. Systemic medicine is necessary for patients with severe conditions. Complications need to be treated in a timely manner.
洪晶. 关注睑板腺功能障碍相关的角结膜病变[J]. 中华眼视光学与视觉科学杂志, 2015, 17(11): 659-661.
Hong Jing. The impact of keratoconjunctivitis associated with meibomian gland dysfunction. Chinese Journal of Optometry Ophthalmology and Visual science, 2015, 17(11): 659-661. DOI: 10.3760/cma.j.issn.1674-845X.2015.11.005
Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading[J]. Ocul Surf,2003,1(3):107-126.
[2]
Kozak I, Bron AJ, Kucharova K, et al. Morphologic and volumetric studies of the meibomian glands in elderly human eyelids[J]. Cornea,2007,26(5):610-614.
[3]
Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary[J]. Invest Ophthalmol Vis Sci,2011,52(4):1922-1929.
[4]
Chew CK, Hykin PG, Jansweijer C, et al. The casual level of meibomian lipids in humans[J]. Curr Eye Res,1993,12(3):255-259.
[5]
Yokoi N, Mossa F, Tiffany JM, et al. Assessment of meibomian gland function in dry eye using meibometry[J]. Arch Ophthalmol,1999,117(6):723-729.
[6]
Yokoi N, Bron AJ, Tiffany J, et al. Reflective meniscometry: a non-invasive method to measure tear meniscus curvature[J]. Br J Ophthalmol,1999,83(1):92-97.
[7]
DEWS. Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the international Dry Eye WorkShop(2007)[J]. Ocul Surf, 2007,5(2):108-152.
[8]
McMonnies CW. Key questions in a dry eye history[J]. J Am Optom Assoc,1986,57(7):512-517.
[9]
Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the Ocular Surface Disease Index[J]. Arch Ophthalmol,2000,118(5):615-621.
[10]
Bandeen-Roche K, Mu?觡oz B, Tielsch JM, et al. Self-reported assessment of dry eye in a population-based setting[J]. Invest Ophthalmol Vis Sci,1997,38(12):2469-2475.
[11]
Johnson, ME, Murphy PJ. Measurement of ocular surface irritation on a linear interval scale with the ocular comfort index[J]. Invest Ophthalmol Vis Sc,2007,48(10):4451-4458.
[12]
Begley CG, Caffery B, Chalmers RL, et al. Use of the dry eye questionnaire to measure symptoms of ocular irritation in patients with aqueous tear deficient dry eye[J]. Cornea,2002,21(7):664-670.
[13]
Finis D, K?觟nig C, Hayajneh J, et al. Six-month effects of a thermodynamic treatment for MGD and implications of meibomian gland atrophy[J]. Cornea,2014,33(12):1265-1270.
[14]
Finis D, Hayajneh J, K?觟nig C, et al. Evaluation of an automated thermodynamic treatment (LipiFlow?誖)system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial[J]. Ocul Surf,2014,12(2):146-154.
[15]
Maskin SL. Intraductal meibomian gland probing relieves symptoms of obstructive meibomian gland dysfunction[J]. Cornea,2010,29(10):1145-1152.